Cognition Therapeutics, Inc. (NASDAQ:CGTX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the six ratings firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $8.30.
A number of research firms have recently issued reports on CGTX. B. Riley upgraded Cognition Therapeutics from a “neutral” rating to a “buy” rating and increased their target price for the company from $1.00 to $1.50 in a report on Thursday, December 19th. HC Wainwright increased their price target on shares of Cognition Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Thursday, December 19th. Finally, Chardan Capital reissued a “buy” rating and set a $11.00 price objective on shares of Cognition Therapeutics in a report on Thursday, December 19th.
View Our Latest Research Report on CGTX
Cognition Therapeutics Trading Up 9.5 %
Hedge Funds Weigh In On Cognition Therapeutics
Large investors have recently bought and sold shares of the stock. Virtu Financial LLC bought a new stake in Cognition Therapeutics in the 3rd quarter valued at $27,000. Mercer Global Advisors Inc. ADV boosted its stake in Cognition Therapeutics by 33.4% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock valued at $159,000 after buying an additional 24,050 shares in the last quarter. Sigma Planning Corp boosted its stake in Cognition Therapeutics by 14.6% in the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock valued at $92,000 after buying an additional 25,050 shares in the last quarter. Finally, CM Management LLC lifted its holdings in Cognition Therapeutics by 14.3% during the 2nd quarter. CM Management LLC now owns 200,000 shares of the company’s stock valued at $332,000 after purchasing an additional 25,000 shares during the last quarter. 43.35% of the stock is currently owned by institutional investors and hedge funds.
Cognition Therapeutics Company Profile
Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.
Recommended Stories
- Five stocks we like better than Cognition Therapeutics
- Insider Trades May Not Tell You What You Think
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
- Stock Splits, Do They Really Impact Investors?
- Top 3 ETFs to Hedge Against Inflation in 2025
- Manufacturing Stocks Investing
- These 3 Chip Stock Kings Are Still Buys for 2025
Receive News & Ratings for Cognition Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cognition Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.